There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Icon (ICLR – Research Report), Glaukos (GKOS – Research Report) and Zai Lab (ZLAB – Research Report) with bullish sentiments.
Icon (ICLR)
In a report released yesterday, Derik De Bruin from Bank of America Securities reiterated a Buy rating on Icon, with a price target of $305.00. The company’s shares closed last Tuesday at $271.19, close to its 52-week high of $288.50.
According to TipRanks.com, Bruin is a 3-star analyst with an average return of
Currently, the analyst consensus on Icon is a Strong Buy with an average price target of $303.30, which is an 12.0% upside from current levels. In a report issued on January 4, Truist Financial also maintained a Buy rating on the stock with a $357.00 price target.
See the top stocks recommended by analysts >>
Glaukos (GKOS)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Glaukos, with a price target of $83.00. The company’s shares closed last Tuesday at $86.55, close to its 52-week high of $88.26.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Glaukos has an analyst consensus of Moderate Buy, with a price target consensus of $88.00.
Zai Lab (ZLAB)
In a report released today, David Li from Bank of America Securities maintained a Buy rating on Zai Lab, with a price target of $37.00. The company’s shares closed last Tuesday at $26.56, close to its 52-week low of $22.35.
According to TipRanks.com, Li is ranked #8225 out of 8658 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zai Lab with a $69.14 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ICLR:
